QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

REPL

QT78Replimune Group, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
10.19
+0.19+1.90%
OverviewShort InterestFilings
REPLQT78Replimune Group, Inc.·NASDAQ
OverviewShort InterestFilings
10.19+1.90%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-
Insider Own-
Shs Outstand-
Perf Week18.21%
Market Cap825.73MForward P/E-EPS next Y-1.18Insider Trans-Shs Float-Perf Month116.81%
Enterprise Value779.12MPEG0.23EPS next Q-0.63Inst Own-Short Float-Perf Quarter47.90%
Income-281985494.00P/S0.00EPS this Y-Inst Trans-Short Ratio-Perf Half Y6.04%
Sales-P/B4.38EPS next Y34.94%ROA-94.38%Short Interest-Perf YTD4.84%
Book/sh-P/C-EPS next 5Y-ROE-102.69%52W High13.24 -23.04%Perf Year7.15%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-113.17%52W Low1.50 579.33%Perf 3Y-
Dividend Est.-EV/EBITDA-2.50Sales past 3/5Y-Gross Margin0.00%Volatility6.12% 13.33%Perf 5Y-
Dividend TTM-EV/Sales0.00EPS Y/Y TTM0.00%Oper. Margin0.00%ATR (14)0.86Perf 10Y-
Dividend Ex-Date-Quick Ratio5.60Sales Y/Y TTM-Profit Margin0.00%RSI (14)70.61Recom3.00
Dividend Gr. 3/5Y-Current Ratio5.60EPS Q/Q-21.79%SMA2025.72%Beta0.55Target Price14.00
Payout0.00%Debt/Eq0.36Sales Q/Q-SMA5094.37%Rel Volume0.29Prev Close10.00
Employees479LT Debt/Eq0.17EarningsJul 30SMA20044.47%Avg Volume8.87MPrice10.19
IPO DateJul 20, 2018Option/ShortYes / YesEPS/Sales Surpr.-14.46% -Net Debt/EBITDA0.15Volume2,569,303Change1.90%
Analyst Ratings
DateActionAnalystRatingTarget
Apr-13-26DowngradeJP MorganNeutral → Underweight
Apr-13-26DowngradeCantor FitzgeraldOverweight → Neutral
Apr-13-26DowngradeJefferiesBuy → Hold
Apr-13-26DowngradeWedbushOutperform → Neutral
Apr-13-26DowngradeLeerink PartnersOutperform → Market Perform
Apr-13-26DowngradeHC Wainwright & Co.Buy → Sell
Feb-05-26ReiteratedPiper SandlerOverweight$43 → $14
Nov-03-25UpgradeBMO CapitalUnderperform → Market Perform$27 → $11
Oct-27-25ReiteratedH.C. WainwrightBuy$17 → $12
Oct-27-25UpgradeHC Wainwright & Co.Neutral → Buy
Latest News
Jun-18-26
Jun-18-2603:28PM
Biohaven: Upgrading To Buy On Protein Degraders Pivotal Study InitiationsSeekingAlpha
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
3/31/2025
FY 2024
3/31/2024
FY 2023
3/31/2023
FY 2022
3/31/2022
FY 2021
3/31/2021
FY 2020
3/31/2020
FY 2019
3/31/2019
FY 2018
3/31/2018
FY 2017
3/31/2017
Total Revenue
000
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A000
Gross Profit000
Selling, General and Administrative Excl. Other000
Research and Development189175127
Other Operating Expense736050
Operating Income-262-235-177
Interest Expense874
Unusual Expense
———
Non-Operating Income (Expense)-2-2-3
Net Income Before Taxes-247-215-174
Income Taxes000
Consolidated Net Income-247-216-174
Net Income From Continuing Operations-247-216-174
Net Income-247-216-174
EPS (Recurring)-3.07-3.24-2.99
EPS (Basic, Before Extraordinaries)-3.07-3.24-2.99
EPS (Diluted)-3.07-3.24-2.99
EBITDA-254-228-172
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio
———
Gross Margin
———
Operating Margin
———
Net Margin
———
Shares Outstanding816758
Market Capitalization
———
Operating Lease Expense
———
Insider Trading Volume
$11.07$10.33$9.60$8.87$8.13● Close Price0.00K118.54K237.07K355.61K474.15KUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Sarchi ChristopherChief Commercial OfficerJun 01 '26Sale9.2412,000110,880180,962Jun 03 12:00 AM
Astley-Sparke PhilipDirectorMay 18 '26Sale5.0817,65789,6981,412,414May 20 12:00 AM
Patel SushilChief Executive OfficerMay 18 '26Sale5.0837,324189,606747,492May 20 12:00 AM
Schwendenman AndrewChief Accounting OfficerMay 18 '26Sale5.087,89440,102107,057May 20 12:00 AM
Xynos KonstantinosChief Medical OfficerMay 18 '26Sale5.0814,02371,237235,662May 20 12:00 AM
Sarchi ChristopherChief Commercial OfficerMay 18 '26Sale5.088,62643,820192,962May 20 12:00 AM
Hill Emily LuisaChief Financial OfficerMay 18 '26Sale5.087,81239,685236,556May 20 12:00 AM
Sarchi ChristopherChief Commercial OfficerApr 02 '26Sale8.016,50052,065151,588Apr 06 12:00 AM
Dhingra KapilDirectorDec 09 '25Option Exercise1.756,33811,0923,169Dec 11 12:00 AM
Dhingra KapilDirectorDec 09 '25Sale10.403,16932,9580Dec 11 12:00 AM
Patel SushilChief Executive OfficerDec 02 '25Sale11.1310,000111,300333,576Dec 04 12:00 AM
Sarchi ChristopherChief Commercial OfficerNov 17 '25Sale9.105,20847,393123,088Nov 19 12:00 AM
Xynos KonstantinosChief Medical OfficerNov 17 '25Sale9.107,24865,957139,685Nov 19 12:00 AM
Hill Emily LuisaChief Financial OfficerAug 15 '25Sale5.379,15449,157134,368Aug 19 12:00 AM
Astley-Sparke PhilipDirectorMay 20 '25Sale8.0632,279260,1691,405,071May 22 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR